Arbutus Biopharma
ABUS
ABUS
71 hedge funds and large institutions have $158M invested in Arbutus Biopharma in 2018 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
71
Holders Change
+21
Holders Change %
+42%
% of All Funds
1.63%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
%
% of All Funds
0.02%
New
29
Increased
18
Reduced
11
Closed
8
Calls
$2.01M
Puts
$933K
Net Calls
+$1.08M
Net Calls Change
+$712K
Top Buyers
1 |
BlackRock
New York
|
+$12.4M |
2 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$8.52M |
3 |
State Street
Boston,
Massachusetts
|
+$3.54M |
4 |
Northern Trust
Chicago,
Illinois
|
+$2.16M |
5 |
Goldman Sachs
New York
|
+$1.8M |
Top Sellers
1 |
Axa
Paris,
France
|
-$2.68M |
2 |
D.E. Shaw & Co
New York
|
-$1.75M |
3 |
AC
Ascend Capital
Orinda,
California
|
-$1.45M |
4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.28M |
5 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$951K |